BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension.

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Pulmonary Circulation Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI:10.1002/pul2.12335

Shine Kumar, Lalitha Biswas, Anju Choorakottayil Pushkaran, Raman Krishna Kumar

引用次数: 0

Abstract

Bone morphogenetic protein receptor 2 (BMPR2) mutation is the most common gene mutation implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We describe, for the first time, an excellent clinical response to tyrosine kinase inhibitor imatinib in a patient with heritable PAH from BMPR2 mutation.

查看原文本刊更多论文

一例遗传性肺动脉高压患者的 BMPR2 基因突变和对伊马替尼的临床反应。

骨形态发生蛋白受体 2（BMPR2）突变是肺动脉高压（PAH）发病机制中最常见的基因突变。我们首次描述了一名因 BMPR2 基因突变导致的遗传性 PAH 患者对酪氨酸激酶抑制剂伊马替尼的良好临床反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pulmonary Circulation Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.20

自引率

11.50%

发文量

153

审稿时长

15 weeks

期刊介绍： Pulmonary Circulation''s main goal is to encourage basic, translational, and clinical research by investigators, physician-scientists, and clinicans, in the hope of increasing survival rates for pulmonary hypertension and other pulmonary vascular diseases worldwide, and developing new therapeutic approaches for the diseases. Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a wide readership of specialists in order to improve patient care and treatment outcomes.